Key points are not available for this paper at this time.
There is the need to engage MSM in harm reduction and prevention services following treatment to reduce reinfection risk.
Adu et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: